<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39455668</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Serum uromodulin associates with kidney function and outcome in a cohort of hospitalised COVID-19 patients.</ArticleTitle><Pagination><StartPage>25420</StartPage><MedlinePgn>25420</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25420</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-76372-3</ELocationID><Abstract><AbstractText>This study investigates the prevalence and evaluates the prognostic implications of acute kidney injury (AKI) in COVID-19 patients, with a novel emphasis on the evaluation of serum uromodulin (sUmod) as a potential kidney-specific biomarker. A cohort of hospitalised COVID-19 patients (n = 378) was examined for AKI using standard criteria. In addition to traditional urinary biomarkers, sUmod levels were analysed. Univariable and multivariable regression models were employed to evaluate the association of sUmod and AKI and in-hospital mortality. Levels of sUmod were significantly lower in patients with CKD (91.8 ± 60.7 ng/ml) compared to patients with normal kidney function (204.7 ± 91.7 ng/ml; p &lt; 0.001). 151 patients (40.0%) presented with AKI at the time of hospital admission or developed an AKI during hospitalization. 116 patients (76.8%) had an AKI already at the time of hospital admission. COVID-19 patients with AKI had significantly lower levels of sUmod compared to patients without AKI during hospitalisation (124.8 ± 79.5 ng/ml) vs 214.6 ± 92.3 ng/ml; p &lt; 0.001). The in-hospital mortality rate in this cohort of COVID-19 patients was 15.3%. Patients with AKI had a higher probability for in-hospital death (OR 5.6, CI 1.76 to 17.881, p = 0.004). Patients who died during hospital stay, had significantly lower sUmod levels (129.14 ± 89.56 ng/ml) compared to patients surviving hospitalisation (187.71 ± 96,64 ng/ml; p &lt; 0.001). AKI is frequently associated with COVID-19 in hospitalized patients. Serum uromodulin may emerge as a promising biomarker for AKI in COVID-19 patients. Further research is warranted to explore its clinical application and refine risk stratification in this patient population.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wendt</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1600-6581</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, St. Georg Hospital, Delitzscher Str. 141, 04129, Leipzig, Germany. ralph.wendt@sanktgeorg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Macholz</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, St. Georg Hospital, Delitzscher Str. 141, 04129, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalbitz</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, St. Georg Hospital, Delitzscher Str. 141, 04129, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Nadja</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Finance and Controlling, St. Georg Hospital, Delitzscher Str. 141, 04129, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herbst</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Seekamp 31, 23560, Lübeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammes</LastName><ForeName>Tabea</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Seekamp 31, 23560, Lübeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kai</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Seekamp 31, 23560, Lübeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ankersmit</LastName><ForeName>Hendrik Jan</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Clinic of Thoracic Surgery, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beige</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Kuratorium for Dialysis and Transplantation (KfH) Renal Unit, Hospital St. Georg, Delitzscher Str. 141, 04129, Leipzig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Martin-Luther University Halle/Wittenberg, Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lübbert</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, St. Georg Hospital, Delitzscher Str. 141, 04129, Leipzig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases and Tropical Medicine, Leipzig University Hospital, Liebigstr. 20, 04103, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Graf</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Medical Statistics, Center for Medical Data Science, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Scherberich</LastName><ForeName>Jürgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Clinical Immunology, Klinikum München, 81545, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058949">Uromodulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058949" MajorTopicYN="Y">Uromodulin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AKI</Keyword><Keyword MajorTopicYN="N">Acute kidney injury</Keyword><Keyword MajorTopicYN="N">CKD</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Kidney failure</Keyword><Keyword MajorTopicYN="N">Uromodulin</Keyword><Keyword MajorTopicYN="N">sUmod</Keyword></KeywordList><CoiStatement>VH, MK and TH are employees of EUROIMMUN Medizinische Labordiagnostika AG, a company that commercialises serological assays and co-owns a patent application related to immunoassays for the diagnosis of a SARS-CoV-2 infection. All other authors declare no conflict of interest related to the topic of this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39455668</ArticleId><ArticleId IdType="pmc">PMC11512065</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-76372-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-76372-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brodin &amp; P. Immune determinants of COVID-19 disease presentation and severity. Nat Med27, 28–33 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet395, 497–506 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin, D. A., Gulick, R. M. &amp; Martinez, F. Severe covid-19. N. Engl. J. Med.383, 2451–2460 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32412710</ArticleId></ArticleIdList></Reference><Reference><Citation>Osuchowski, M. F. et al. The COVID-19 puzzle: Deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir. Med.9, 622–642 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102044</ArticleId><ArticleId IdType="pubmed">33965003</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, A. et al. Extrapulmonary manifestations of COVID-19. Nat. Med.26, 1017–1032 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning, Q. et al. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduct. Target Ther.7, 57 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863906</ArticleId><ArticleId IdType="pubmed">35197452</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun, F. et al. SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet396, 597–598 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431179</ArticleId><ArticleId IdType="pubmed">32818439</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles, V. G. &amp; L"utgehetmann, M., Lindenmeyer, M. T. &amp; others.,. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med.383, 590–592 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Brogan, M. &amp; Ross, M. COVID-19 and Kidney Disease. Annu Rev Med74, 1–13 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36108262</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen, J. et al. SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids. Cell Stem Cell29, 217–231 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8709832</ArticleId><ArticleId IdType="pubmed">35032430</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao, B. et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat. Commun.12, 2506 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8096808</ArticleId><ArticleId IdType="pubmed">33947851</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, H. et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int.98, 219–227 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194105</ArticleId><ArticleId IdType="pubmed">32327202</ArticleId></ArticleIdList></Reference><Reference><Citation>Batlle, D. et al. Acute kidney injury in COVID-19: Emerging evidence of a distinct pathophysiology. J. Am. Soc. Nephrol.31, 1380–1383 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7350999</ArticleId><ArticleId IdType="pubmed">32366514</ArticleId></ArticleIdList></Reference><Reference><Citation>Palevsky, P. COVID-19 and AKI: Where do we stand?. J. Am. Soc. Nephrol.32, 1029–1032 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8259685</ArticleId><ArticleId IdType="pubmed">33637516</ArticleId></ArticleIdList></Reference><Reference><Citation>Legrand, M. et al. Pathophysiology of COVID-19-associated acute kidney injury. Nat. Rev. Nephrol.17, 751–764 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8256398</ArticleId><ArticleId IdType="pubmed">34226718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch, J. S. et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int.98, 209–218 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7229463</ArticleId><ArticleId IdType="pubmed">32416116</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver, S. A. et al. The prevalence of acute kidney injury in patients hospitalized with COVID-19 infection: A systematic review and meta-analysis. Kidney Med.3, 83–98 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723763</ArticleId><ArticleId IdType="pubmed">33319190</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, Y. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int.97, 829–838 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110296</ArticleId><ArticleId IdType="pubmed">32247631</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon, T., Sharma, R., Kataria, S. &amp; others. The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A systematic review and meta-analysis. Cureus (2021) 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8045562</ArticleId><ArticleId IdType="pubmed">33880250</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinhandl, E. D. et al. Initial effects of COVID-19 on patients with ESKD. J. Am. Soc. Nephrol.32, 1444–1453 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8259631</ArticleId><ArticleId IdType="pubmed">33833076</ArticleId></ArticleIdList></Reference><Reference><Citation>Crim, M. C., Calloway, D. H. &amp; Margen, S. Creatine metabolism in men: Urinary creatine and creatinine excretions with creatine feeding. J. Nutr.105, 428–438 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1113209</ArticleId></ArticleIdList></Reference><Reference><Citation>Porrini, E. et al. Estimated GFR: Time for a critical appraisal. Nat. Rev. Nephrol.15, 177–190 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30518813</ArticleId></ArticleIdList></Reference><Reference><Citation>Nankivell, B. J. et al. How unmeasured muscle mass affects estimated GFR and diagnostic inaccuracy. EClinicalMedicine1006, 29–30 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7788434</ArticleId><ArticleId IdType="pubmed">33437955</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey, A. S. et al. Strengths and limitations of estimated and measured GFR. Nat. Rev. Nephrol.15, 784 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31578495</ArticleId></ArticleIdList></Reference><Reference><Citation>Orskov, I., Ferencz, A. &amp; F., O. Tamm–Horsfall protein or uromucoid is the normal urinary slime that traps type 1 fimbriated Escherichia coli. Lancet315, 887–888 (1980).</Citation><ArticleIdList><ArticleId IdType="pubmed">6103253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo, L. et al. Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int.66, 1159–1166 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15327412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo, L. et al. Ablation of the Tamm-Horsfall protein gene increases susceptibility of mice to bladder colonization by type 1-fimbriated Escherichia coli. Am. J. Physiol. Renal Physiol.286, F795–F802 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14665435</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates, J. M. et al. Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int.65, 791–797 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14871399</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf, M. T., Wu, X. R. &amp; Huang, C. Uromodulin upregulates TRPV5 by impairing caveolin-mediated endocytosis. Kidney Int.84, 130–137 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700562</ArticleId><ArticleId IdType="pubmed">23466996</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie, M. et al. Uromodulin regulates renal magnesium homeostasis through the ion channel transient receptor potential melastatin 6 (TRPM6). J. Biol. Chem.293, 16488–16502 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6200953</ArticleId><ArticleId IdType="pubmed">30139743</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaeffer, C., Devuyst, O. &amp; Rampoldi, L. Uromodulin: Roles in health and disease. Annu. Rev. Physiol.83, 477–501 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33566673</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmann, S., Koeppen-Hagemann, I. &amp; Kriz, W. Ultrastructural localization of Tamm-Horsfall glyeoprotein (THP) in rat kidney as revealed by protein A-gold immunocytochemistry. Histochemistry83, 531–538 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">3910623</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Achkar, T. M. et al. Tamm-Horsfall protein translocates to the basolateral domain of thick ascending limbs, interstitium, and circulation during recovery from acute kidney injury. Am. J. Physiol. Renal Physiol.304, F1066-1075 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625838</ArticleId><ArticleId IdType="pubmed">23389456</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherberich, J. E. et al. Serum uromodulin-a marker of kidney function and renal parenchymal integrity. Nephrol. Dial Transplant.33, 284–295 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837243</ArticleId><ArticleId IdType="pubmed">28206617</ArticleId></ArticleIdList></Reference><Reference><Citation>Brezis, M. &amp; Rosen, S. Hypoxia of the renal medulla—Its implications for disease. N. Engl. J. Med.332, 647–655 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7845430</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen, S. &amp; Stillman, I. Acute tubular necrosis is a syndrome of physiologic and pathologic dissociation. J. Am. Soc. Nephrol.19, 871–875 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18235086</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyman, S. N., Rosenberger, C. &amp; Rosen, S. Experimental ischemia-reperfusion: Biases and myths-the proximal vs distal hypoxic tubular injury debate revisited. Kidney Int.77, 9–16 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19759527</ArticleId></ArticleIdList></Reference><Reference><Citation>Schley, G. et al. Hypoxia-inducible transcription factors stabilization in the thick ascending limb protects against ischemic acute kidney injury. J. Am. Soc. Nephrol.22, 2004–2015 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3279994</ArticleId><ArticleId IdType="pubmed">21921145</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharfuddin, A. A. &amp; Molitoris, B. Pathophysiology of ischemic acute kidney injury. Nat. Rev. Nephrol.7, 189–200 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21364518</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivin, E. et al. Uromodulin and nephron mass. Clin. J. Am. Soc. Nephrol.13, 1556–1557 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6218822</ArticleId><ArticleId IdType="pubmed">30054352</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruijm, M. et al. Associations of urinary uromodulin with clinical characteristics and markers of tubular function in the general population. Clin. J. Am. Soc. Nephrol.11, 70–80 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702229</ArticleId><ArticleId IdType="pubmed">26683888</ArticleId></ArticleIdList></Reference><Reference><Citation>Youhanna, S. et al. Determination of uromodulin in human urine: Influence of storage and processing. Nephrol. Dial Transplant.29, 136–145 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24097801</ArticleId></ArticleIdList></Reference><Reference><Citation>Steubl, D., Block, M., Herbst, V. &amp; others. Plasma uromodulin correlates with kidney function and identifies early stages in chronic kidney disease patients. Medicine (Baltimore)95 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4998896</ArticleId><ArticleId IdType="pubmed">26962815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta, R. L., Kellum, J. A., Shah, S. V. &amp; others. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care11 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206446</ArticleId><ArticleId IdType="pubmed">17331245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross, O., Moerer, O., Weber, M. &amp; others. COVID-19-associated nephritis: Early warning for disease severity and complications? Lancet395 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202828</ArticleId><ArticleId IdType="pubmed">32423587</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, L. et al. AKI in hospitalized patients with COVID-19. J. Am. Soc. Nephrol.32, 151–160 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894657</ArticleId><ArticleId IdType="pubmed">32883700</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina, R. et al. Incidence and outcomes of acute kidney injury in COVID-19: A systematic review. Blood Purif.51, 199–212 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8339045</ArticleId><ArticleId IdType="pubmed">34130296</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari-Oori, M. et al. Clinical, biological and molecular aspects of COVID-19. Adv. Exp. Med. Biol.1321, 309–324 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33656736</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorling, A. et al. Association between CKD, obesity, cardiometabolic risk factors, and severe COVID-19 outcomes. Kidney Int. Rep.8, 775–784 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9840229</ArticleId><ArticleId IdType="pubmed">36685734</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabb, H. et al. Inflammation in AKI: Current understanding, key questions, and knowledge gaps. J. Am. Soc. Nephrol.27, 371–379 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731128</ArticleId><ArticleId IdType="pubmed">26561643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali, H. et al. Survival rate in acute kidney injury superimposed COVID-19 patients: A systematic review and meta-analysis. Ren. Fail.42, 393–397 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241495</ArticleId><ArticleId IdType="pubmed">32340507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe, B. et al. Kidney outcomes in long COVID. J. Am. Soc. Nephrol.32, 2851–2862 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8806085</ArticleId><ArticleId IdType="pubmed">34470828</ArticleId></ArticleIdList></Reference><Reference><Citation>Long, J. D. et al. COVID-19 survival and its impact on chronic kidney disease. Transl. Res.241, 70–82 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579714</ArticleId><ArticleId IdType="pubmed">34774843</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarr, D. et al. Estimating GFR by serum creatinine, cystatin C, and beta2-microglobulin in older adults: results from the Canadian study of longevity in type 1 diabetes. Kidney Int. Rep.4, 786–796 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551543</ArticleId><ArticleId IdType="pubmed">31194091</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado, G. E. et al. Serum uromodulin and mortality risk in patients undergoing coronary angiography. J. Am. Soc. Nephrol.28, 2201–2210 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5491294</ArticleId><ArticleId IdType="pubmed">28242751</ArticleId></ArticleIdList></Reference><Reference><Citation>Then, C. et al. Serum uromodulin is inversely associated with biomarkers of subclinical inflammation in the population-based KORA F4 study. Clin. Kidney J.14, 1618–1625 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248959</ArticleId><ArticleId IdType="pubmed">34221377</ArticleId></ArticleIdList></Reference><Reference><Citation>Then, C. et al. Serum uromodulin and decline of kidney function in older participants of the population-based KORA F4/FF4 study. Clin. Kidney J.14, 205–211 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857794</ArticleId><ArticleId IdType="pubmed">33564420</ArticleId></ArticleIdList></Reference><Reference><Citation>Steubl, D. et al. Association of serum uromodulin with death, cardiovascular events, and kidney failure in CKD. Clin. J. Am. Soc. Nephrol.15, 616–624 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269219</ArticleId><ArticleId IdType="pubmed">32291270</ArticleId></ArticleIdList></Reference><Reference><Citation>Alesutan, I. et al. Circulating uromodulin inhibits vascular calcification by interfering with pro-inflammatory cytokine signalling. Cardiovasc. Res.117, 930–941 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32243494</ArticleId></ArticleIdList></Reference><Reference><Citation>Steubl, D. et al. Serum uromodulin predicts graft failure in renal transplant recipients. Biomarkers22, 171–177 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27790922</ArticleId></ArticleIdList></Reference><Reference><Citation>Then, C. et al. Serum uromodulin and risk for cardiovascular morbidity and mortality in the community-based KORA F4 study. Atherosclerosis297, 1–7 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32058862</ArticleId></ArticleIdList></Reference><Reference><Citation>Menez, S. et al. Prognostic significance of urinary biomarkers in patients hospitalized with COVID-19. Am. J. Kidney Dis.79, 257–267 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542781</ArticleId><ArticleId IdType="pubmed">34710516</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFavers, K. &amp; Garimella, P. Uromodulin: More than a marker for chronic kidney disease progression. Curr. Opin. Nephrol. Hypertens.32, 271–277 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36912260</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>